Up a level |
Donovan-Banfield, I'ah ORCID: 0000-0002-5124-2427, Penrice-Randal, Rebekah ORCID: 0000-0002-0653-2097, Goldswain, Hannah ORCID: 0000-0003-4194-8714, Rzeszutek, Aleksandra M, Pilgrim, Jack, Bullock, Katie, Saunders, Geoffrey, Northey, Josh, Dong, Xiaofeng, Ryan, Yan ORCID: 0000-0002-4708-5350 et al (show 24 more authors)
(2022)
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
NATURE COMMUNICATIONS, 13 (1).
7284-.
Challenger, Elizabeth ORCID: 0000-0002-8978-6067, Penchala, Sujan Dilly, Hale, Colin, Fitzgerald, Richard, Walker, Lauren ORCID: 0000-0002-3827-4387, Reynolds, Helen ORCID: 0000-0001-7443-4520, Chiong, Justin, Fletcher, Tom, Khoo, Saye and Else, Laura
(2023)
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233.
115436-.
Khoo, Saye H ORCID: 0000-0002-2769-0967, FitzGerald, Richard, Saunders, Geoffrey, Middleton, Calley, Ahmad, Shazaad, Edwards, Christopher J, Hadjiyiannakis, Dennis, Walker, Lauren ORCID: 0000-0002-3827-4387, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186 et al (show 80 more authors)
(2022)
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
The Lancet Infectious Diseases, 23 (2).
pp. 183-195.
Walker, Lauren E ORCID: 0000-0002-3827-4387, FitzGerald, Richard, Saunders, Geoffrey, Lyon, Rebecca, Fisher, Michael, Martin, Karen, Eberhart, Izabela, Woods, Christie, Ewings, Sean, Hale, Colin et al (show 23 more authors)
(2022)
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 111 (3).
pp. 585-594.
Khoo, Saye H ORCID: 0000-0002-2769-0967, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren ORCID: 0000-0002-3827-4387, Tansley-Hancock, Olana, Greenhalf, William et al (show 28 more authors)
(2021)
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76 (12).
pp. 3286-3295.
FitzGerald, Richard, Dickinson, Laura ORCID: 0000-0001-5557-9396, Else, Laura, Fletcher, Thomas, Hale, Colin, Amara, Alieu ORCID: 0000-0002-1137-2948, Walker, Lauren ORCID: 0000-0002-3827-4387, Penchala, Sujan Dilly, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186 et al (show 9 more authors)
(2022)
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
CLINICAL INFECTIOUS DISEASES, 75 (1).
E525-E528.
Amara, Alieu ORCID: 0000-0002-1137-2948, Penchala, Sujan Dilly, Else, Laura, Hale, Colin, FitzGerald, Richard, Walker, Lauren ORCID: 0000-0002-3827-4387, Lyons, Rebecca, Fletcher, Tom and Khoo, Saye ORCID: 0000-0002-2769-0967
(2021)
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206.
114356-.